Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 1142-1148

  Baldoni, Daniela ^a   Haschke, Manuel ^a   Rajacic, Zarko ^a   Zimmerli, Werner ^b   Trampuz, Andrej ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Kantonsspital Liestal   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; LINEZOLID; RIFAMPICIN; SANDOZ AG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOPLANKTON; BACTERIUM ADHERENCE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; ERADICATION THERAPY; FOREIGN BODY REACTION; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOREIGN-BODY REACTION; GUINEA PIGS; INJECTIONS, INTRAPERITONEAL; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MODELS, ANIMAL; OXAZOLIDINONES; PLANKTON; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 62949177836     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00775-08     Document Type: Article

References (44)

1. Acocella, G. 1983. Pharmacokinetics and metabolism of rifampin in humans. Rev. Infect. Dis. 5(Suppl. 3):S428-S432.
2. la. Andes, D., M. L. Van Ogtrop, J. Peng, and W. A. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
3. Bassetti, M., A. Di Biagio, G. Cenderello, V. Del Bono, A. Palermo, M. Crueiani, and D. Bassetti. 2001. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA). J. Infect.43:148-149.
4. Blaser, J., P. Vergeres, A. F. Widmer, and W. Zimmerli. 1995. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob. Agents Chemother. 39:1134-1139.
5. Bonomo, R. A. 2000. Multiple antibiotic-resistant bacteria in long-term-care facilities: an emerging problem in the practice of infectious diseases.Clin.Infect. Dis. 31:1414-1422.
6. Brandt, C. M., M. C. Dufty, E. F. Berbari, A. D. Hanssen, J. M. Steckelberg, and D. R. Osmon. 1999. Staphylococcus aureus prosthetic joint infection treated with prosthesis removal and delayed reimplantation arthroplasty. Mayo Clin. Proc. 74:553-558.
7. Clinical and Laboratory Standards Institute. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Document M7-A7. Clinical and Laboratory Standards Institute, Wayne. PA.
8. Donlan, R. M. 2002. Biofilms: microbial life on surfaces. Emerg. Infect. Dis.8:881-890.
9. Donlan, R, M., and J. W, Costerton, 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15:167-193.
10. Drancourt, M., A. Stein, J. N. Argenson, R. Roiron, P. Groulier, and D. Raoult. 1997. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J. Antimicrob. Chemother. 39:235-240.
11. Gee, T., R. Ellis, G. Marshall, J. Andrews, J. Ashby, and R. Wise. 2001. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother. 45:1843-1846.
12. Grohs, P., M. D. Kitzis, and L. Gutmann. 2003. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin. ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:418-420.
13. Jacqueline, C, J. Caillon, V. Le Mabecque, A. F. Miegeville, P. Y. Donnio, D. Bugnon, and G, Potel. 2003. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin resistant Staphylococcus aureus by time-kill curve methods. J. Antimicrob. Chemother. 51:857-864.
14. Jorgensen, J. H., M. L. McElmeel, and C. W. Trippy. 1997. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimicrob. Agents Chemother. 41:465-467.
15. Laffer, R. R., P. Graber, P. E. Ochsner, and W. Zimmerli. 2006. Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre. Clin. Microbiol. Infect. 12:433-439.
16. Lorian, V, 2005. Antibiotics in laboratory medicine, 5th ed. Lippincott Williams & Wilkins Co., Philadelphia, PA.
17. Manfredi, R. 2006. Update on the appropriate use of linezolid in clinical practice. Ther. Clin. Risk Manag. 2:455-464.
18. Murillo, O., A. Domenech, A. Garcia, F. Tubau, C. Cabellos, F. Gudiol, and J. Ariza. 2006. Efficacy of high doses of levofloxacin in experimental foreign body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 50:4011-4017.
19. Murray, P. R., E. J. Baron, J, H. Jorgensen, M. A, Pfaller, and R. H. Yolken. 2003. Manual of clinical microbiology, 8th ed. ASM Press, Washington, DC.
20. Prugger, V., S. Egner, R. Windhager, M. Mitteregger, G. Bertha, and C. Wenisch. 2004. Treatment with linezolid and rifampicin for 18 months for recurrent infection of a megaprosthesis in a patient with Ewing's sarcoma. Int. J. Antimicrob. Agents 24:628-630.
21. Rybak, M. J., D. M. Cappelletty, T. Moldovan, J. R. Aeschlimann, and G. W. Kaatz. 1998. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob. Agents Chemother. 42:721-724.
22. Reference deleted.
23. Schwank, S., Z. Rajacic, W. Zimmerli, and J. Blaser. 1998. Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics. Antimicrob. Agents Chemother. 42:895-898.
24. Shams, W. E., and R. P. Rapp. 2004. Methicillin-resistant staphylococcal infections: an important consideration for orthopedic surgeons. Orthopedics 27:565-568.
25. Shinabarger, D. L., K. R. Marotti, R. W. Murray, A. H. Lin, E. P. Melchior, S, M. Swaney, D. S. Dunyak, W. F. Demyan, and J. M. Buysse. 1997. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother. 41:2132-2136.
26. Soriano, A., S. Garcia, G. Bori, M. Almela, X. Gallart, F. Macule, J. Sierra, J. A. Martinez, S. Suso, and J. Mensa. 2006. Treatment of acute post-surgical infection of joint arthroplasty. Clin. Microbiol. Infect. 12:930-933.
27. Soriano, A., J. Gomez, L. Gomez, J. R. Azanza, R. Perez, F. Romero, M. Pons, F. Bella, M. Velasco, and J. Mensa. 2007. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur. J. Clin. Microbiol. Infect. Dis. 26:353-356.
28. Stalker, D. J., and G. L. Jungbluth. 2003. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin. Pharmacokinet. 42:1129-1140.
29. Swaney, S. M., H. Aoki, M. C. Ganoza, and D. L. Shinabarger. 1998. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. 42:3251-3255.
30. Sweeney, M, T., and G. E. Zurenko. 2003. In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected gram-negative organisms. Antimicrob. Agents Chemother. 47:1902-1906.
31. Thomson, C. J. 1999. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. J. Antimicrob. Chemother. 43(Suppl. A):31-40.
32. Trampuz, A., C. K. Murphy, D. M. Rothstein, A. F. Widmer, R. Landmann, and W, Zimmerli. 2007. Efficacy of a novel rifamycin derivative, AB1-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. Antimicrob. Agents Chemother. 51:2540-2545.
33. Trampuz, A., and W. Zimmerli, 2005. New strategies for the treatment of infections associated with prosthetic joints. Curr. Opin. Investig. Drugs 6:185-190.
34. Tverdek, F, P., C. W. Crank, and J. Segreti. 2008. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care. Crit. Care Clin. 24:249-260.
35. Widmer, A. F., R, Frei, Z. Rajacic, and W, Zimmerli. 1990. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J. Infect. Dis. 162:96-102.
36. Widmer, A. F., A. Gaechter, P. E, Ochsner, and W, Zimmerli. 1992. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. 14:1251-1253.
37. Widmer, A. F., A. Wiestner, R. Frei, and W. Zimmerli. 1991. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device related infections. Antimicrob. Agents Chemother. 35:741-746.
38. Zavasky, D. M., and M. A. Sande. 1998. Reconsideration of rifampin: a unique drug for a unique infection. JAMA 279:1575-1577.
39. Zimmerli, W. 1993. Experimental models in the investigation of device related infections. J. Antimicrob. Chemother. 31(Suppl. D):97-102.
40. Zimmerli, W., R. Frei, A. F. Widmer, and Z. Rajacic. 1994. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J. Antimicrob. Chemother. 33:959-967.
41. Zimmerli, W., P. D. Lew, and F. A. Waldvogel. 1984. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J. Clin. Investig. 73:1191-1200.
42. Zimmerli, W., A. Trampuz, and P. E. Ochsner. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654.
43. Zimmerli, W., F. A. Waldvogel, P. Vaudaux, and U. E. Nydegger. 1982. Pathogenesis of foreign body infection: description and characteristics of an animal model. J. Infect. Dis. 146:487-497.
44. Zimmerli, W., A. F. Widmer, M. Blatter, R. Frei, P. E. Ochsner, et al. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. JAMA 279:1537-1541.